Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 340

1.

Pharmacodynamic profiling of modithromycin: assessment in a pneumococcal murine pneumonia model.

Maglio D, Sun HK, Patel T, Banevicius MA, Nightingale CH, Arya A, Wang G, Chen Z, Phan LT, Nicolau DP.

Int J Antimicrob Agents. 2014 Jun;43(6):540-6. doi: 10.1016/j.ijantimicag.2014.01.029. Epub 2014 Mar 19.

PMID:
24703590
2.

Infusion phlebitis: relative incidence associated with cefuroxime administered by intermittent and continuous infusion.

Owens CA, Ambrose PG, Quintiliani R, Nightingale CH, Nicolau DP.

Clin Drug Investig. 1998;15(6):531-5. No abstract available.

PMID:
18370511
3.

A survey of the quality of generic clarithromycin products from 18 countries.

Nightingale CH.

Clin Drug Investig. 2005;25(2):135-52.

PMID:
17523763
4.

Impact of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species on clinical outcomes and hospital costs: a matched cohort study.

Lee SY, Kotapati S, Kuti JL, Nightingale CH, Nicolau DP.

Infect Control Hosp Epidemiol. 2006 Nov;27(11):1226-32. Epub 2006 Oct 23.

PMID:
17080381
5.

Population pharmacokinetic analysis and dosing regimen optimization of meropenem in adult patients.

Li C, Kuti JL, Nightingale CH, Nicolau DP.

J Clin Pharmacol. 2006 Oct;46(10):1171-8.

PMID:
16988206
6.

Comparative in vivo efficacy of meropenem, imipenem, and cefepime against Pseudomonas aeruginosa expressing MexA-MexB-OprM efflux pumps.

Ong CT, Tessier PR, Li C, Nightingale CH, Nicolau DP.

Diagn Microbiol Infect Dis. 2007 Feb;57(2):153-61. Epub 2006 Aug 23.

PMID:
16930925
7.

In vivo immunomodulatory profile of telithromycin in a murine pneumococcal infection model.

Niclau DP, Tessier pR, Rubinstein I, Nightingale CH.

Pharmazie. 2006 Apr;61(4):343-7.

PMID:
16649552
8.

Tissue penetration of telavancin after intravenous administration in healthy subjects.

Sun HK, Duchin K, Nightingale CH, Shaw JP, Seroogy J, Nicolau DP.

Antimicrob Agents Chemother. 2006 Feb;50(2):788-90.

9.

Population pharmacokinetics and pharmacodynamics of meropenem in pediatric patients.

Du X, Li C, Kuti JL, Nightingale CH, Nicolau DP.

J Clin Pharmacol. 2006 Jan;46(1):69-75.

PMID:
16397286
10.
11.
12.

Intrapulmonary concentrations of telithromycin: clinical implications for respiratory tract infections due to Streptococcus pneumoniae.

Ong CT, Dandekar PK, Sutherland C, Nightingale CH, Nicolau DP.

Chemotherapy. 2005 Oct;51(6):339-46. Epub 2005 Oct 13.

PMID:
16224186
13.

Evaluation of telithromycin against Streptococcus pneumoniae with ribosomal mutations utilizing in vitro time-kill methodology.

Dandekar PK, Tessier PR, Farrell DJ, Nightingale CH, Nicolau DP.

Int J Antimicrob Agents. 2005 Oct;26(4):331-4.

PMID:
16144757
14.

Penetration, efflux and intracellular activity of tigecycline in human polymorphonuclear neutrophils (PMNs).

Ong CT, Babalola CP, Nightingale CH, Nicolau DP.

J Antimicrob Chemother. 2005 Sep;56(3):498-501. Epub 2005 Jul 15.

PMID:
16024591
15.

Comparison of pharmacodynamic target attainment between healthy subjects and patients for ceftazidime and meropenem.

Kuti JL, Horowitz S, Nightingale CH, Nicolau DP.

Pharmacotherapy. 2005 Jul;25(7):935-41.

PMID:
16006272
16.

Population pharmacokinetics and pharmacodynamics of piperacillin/tazobactam in patients with complicated intra-abdominal infection.

Li C, Kuti JL, Nightingale CH, Mansfield DL, Dana A, Nicolau DP.

J Antimicrob Chemother. 2005 Aug;56(2):388-95. Epub 2005 Jul 7.

PMID:
16002420
17.

A sensitive assay of amoxicillin in mouse serum and broncho-alveolar lavage fluid by liquid-liquid extraction and reversed-phase HPLC.

Du X, Li C, Sun HK, Nightingale CH, Nicolau DP.

J Pharm Biomed Anal. 2005 Sep 15;39(3-4):648-52.

PMID:
15935600
18.

Assessment of the efficacy of telithromycin simulating human exposures against S. pneumoniae with ribosomal mutations in a murine pneumonia model.

Dandekar PK, Williams P, Tessier PR, Farrell DJ, Nightingale CH, Nicolau DP.

Int J Antimicrob Agents. 2005 Jun;25(6):530-4.

PMID:
15894464
19.

Pharmacokinetic profile of tigecycline in serum and skin blister fluid of healthy subjects after multiple intravenous administrations.

Sun HK, Ong CT, Umer A, Harper D, Troy S, Nightingale CH, Nicolau DP.

Antimicrob Agents Chemother. 2005 Apr;49(4):1629-32.

20.

The clinical and economic benefits of administering piperacillin-tazobactam by continuous infusion.

Kotapati S, Kuti JL, Geissler EC, Nightingale CH, Nicolau DP.

Intensive Crit Care Nurs. 2005 Apr;21(2):87-93. Review.

PMID:
15778072
21.

Pharmacodynamic profile of ertapenem against Klebsiella pneumoniae and Escherichia coli in a murine thigh model.

Maglio D, Banevicius MA, Sutherland C, Babalola C, Nightingale CH, Nicolau DP.

Antimicrob Agents Chemother. 2005 Jan;49(1):276-80.

22.

Pharmacodynamic profile of telithromycin against macrolide- and fluoroquinolone-resistant Streptococcus pneumoniae in a neutropenic mouse thigh model.

Tessier PR, Mattoes HM, Dandekar PK, Nightingale CH, Nicolau DP.

Antimicrob Agents Chemother. 2005 Jan;49(1):188-94.

23.

Quantitation of tigecycline, a novel glycylcycline [corrected] by liquid chromatography.

Li C, Sutherland CA, Nightingale CH, Nicolau DP.

J Chromatogr B Analyt Technol Biomed Life Sci. 2004 Nov 25;811(2):225-9. Erratum in: J Chromatogr B Analyt Technol Biomed Life Sci. 2005 May 5;819(1):201.

PMID:
15522724
24.

Simultaneous analysis of piperacillin and tazobactam in rabbits: application to pharmacokinetic study.

Li C, Xuan D, Ye M, Nightingale CH, Nicolau DP.

Biomed Chromatogr. 2005 Jan;19(1):99-106.

PMID:
15484223
25.

Effect of adjunctive treatment with gamma interferon against Pseudomonas aeruginosa pneumonia in neutropenic and non-neutropenic hosts.

Babalola CP, Nightingale CH, Nicolau DP.

Int J Antimicrob Agents. 2004 Sep;24(3):219-25.

PMID:
15325424
26.

Clinical and economic benefits of a meropenem dosage strategy based on pharmacodynamic concepts.

Kotapati S, Nicolau DP, Nightingale CH, Kuti JL.

Am J Health Syst Pharm. 2004 Jun 15;61(12):1264-70.

PMID:
15259757
27.

Optimizing pharmacodynamic target attainment using the MYSTIC antibiogram: data collected in North America in 2002.

Kuti JL, Nightingale CH, Nicolau DP.

Antimicrob Agents Chemother. 2004 Jul;48(7):2464-70.

28.

Differential efficacy of clarithromycin in lung versus thigh infection models.

Maglio D, Capitano B, Banevicius MA, Geng Q, Nightingale CH, Nicolau DP.

Chemotherapy. 2004 Jun;50(2):63-6.

PMID:
15211079
29.

Pharmacokinetic properties and stability of continuous-infusion meropenem in adults with cystic fibrosis.

Kuti JL, Nightingale CH, Knauft RF, Nicolau DP.

Clin Ther. 2004 Apr;26(4):493-501.

PMID:
15189746
30.

Review of the pharmacodynamics of antibiotic use in animal food production.

Florea NF, Nightingale CH.

Diagn Microbiol Infect Dis. 2004 Jun;49(2):105-8. Review.

PMID:
15183859
31.

Population pharmacokinetics of gentamicin in hospitalized patients receiving once-daily dosing.

Xuan D, Nicolau DP, Nightingale CH.

Int J Antimicrob Agents. 2004 Mar;23(3):291-5.

PMID:
15164971
32.

Determination of the in vivo pharmacodynamic profile of cefepime against extended-spectrum-beta-lactamase-producing Escherichia coli at various inocula.

Maglio D, Ong C, Banevicius MA, Geng Q, Nightingale CH, Nicolau DP.

Antimicrob Agents Chemother. 2004 Jun;48(6):1941-7.

33.

Prevalence of extended spectrum beta-lactamase producing Escherichia coli and Klebsiella isolates in a large community teaching hospital in Connecticut.

Dandekar PK, Tetreault J, Quinn JP, Nightingale CH, Nicolau DP.

Diagn Microbiol Infect Dis. 2004 May;49(1):37-9.

PMID:
15135498
34.

Adjunctive efficacy of granulocyte colony-stimulating factor on treatment of Pseudomonas aeruginosa pneumonia in neutropenic and non-neutropenic hosts.

Babalola CP, Nightingale CH, Nicolau DP.

J Antimicrob Chemother. 2004 Jun;53(6):1098-100. Epub 2004 May 5.

PMID:
15128727
35.

Efficacy of clarithromycin against Streptococcus pneumoniae expressing mef(A)-mediated resistance.

Maglio D, Capitano B, Banevicius MA, Tessier PR, Nightingale CH, Nicolau DP.

Int J Antimicrob Agents. 2004 May;23(5):498-501.

PMID:
15120730
36.
37.
38.

Pharmacoeconomic analysis of amphotericin B lipid complex versus liposomal amphotericin B in the treatment of fungal infections.

Kuti JL, Kotapati S, Williams P, Capitano B, Nightingale CH, Nicolau DP.

Pharmacoeconomics. 2004;22(5):301-10.

PMID:
15061680
39.

Pharmacodynamics of moxifloxacin and levofloxacin at simulated epithelial lining fluid drug concentrations against Streptococcus pneumoniae.

Florea NR, Tessier PR, Zhang C, Nightingale CH, Nicolau DP.

Antimicrob Agents Chemother. 2004 Apr;48(4):1215-21.

40.

Emerging Pseudomonas aeruginosa resistance: implications in clinical practice.

Ong CT, Kuti JL, Nightingale CH, Nicolau DP.

Conn Med. 2004 Jan;68(1):11-5. Review. No abstract available.

PMID:
14752913
41.

Pharmacodynamics of meropenem and imipenem against Enterobacteriaceae, Acinetobacter baumannii, and Pseudomonas aeruginosa.

Kuti JL, Florea NR, Nightingale CH, Nicolau DP.

Pharmacotherapy. 2004 Jan;24(1):8-15.

PMID:
14740783
42.

Pharmacodynamic study of beta-lactams alone and in combination with beta-lactamase inhibitors against Pseudomonas aeruginosa possessing an inducible beta-lactamase.

Li C, Nicolau DP, Lister PD, Quintiliani R, Nightingale CH.

J Antimicrob Chemother. 2004 Feb;53(2):297-304. Epub 2004 Jan 16.

PMID:
14729755
43.

Impact of pharmacodynamics on dosing of macrolides, azalides, and ketolides.

Maglio D, Nicolau DP, Nightingale CH.

Infect Dis Clin North Am. 2003 Sep;17(3):563-77, vi. Review.

PMID:
14711077
44.

Beneficial pharmacokinetic interaction between cyclosporine and itraconazole in renal transplant recipients.

Florea NR, Capitano B, Nightingale CH, Hull D, Leitz GJ, Nicolau DP.

Transplant Proc. 2003 Dec;35(8):2873-7.

PMID:
14697925
45.

Bactericidal effect of cethromycin (ABT-773) in an immunocompetent murine pneumococcal pneumonia model.

Capitano B, Maglio D, Banevicius MA, Nightingale CH, Nicolau DP.

Int J Antimicrob Agents. 2003 Dec;22(6):588-93.

PMID:
14659656
46.

Cost analysis of continuous versus intermittent infusion of piperacillin-tazobactam: a time-motion study.

Florea NR, Kotapati S, Kuti JL, Geissler EC, Nightingale CH, Nicolau DP.

Am J Health Syst Pharm. 2003 Nov 15;60(22):2321-7.

PMID:
14652981
47.

Use of Monte Carlo simulation to design an optimized pharmacodynamic dosing strategy for meropenem.

Kuti JL, Dandekar PK, Nightingale CH, Nicolau DP.

J Clin Pharmacol. 2003 Oct;43(10):1116-23. Erratum in: J Clin Pharmacol. 2005 Mar;45(3):357.

PMID:
14517194
48.

Simultaneous determination of ticarcillin and clavulanate in rabbit serum and tissue cage fluid by liquid chromatography.

Li C, Geng Q, Nicolau DP, Nightingale CH.

J Chromatogr B Analyt Technol Biomed Life Sci. 2003 Sep 5;794(2):227-36.

PMID:
12954375
49.

Pharmacokinetics of meropenem 0.5 and 2 g every 8 hours as a 3-hour infusion.

Dandekar PK, Maglio D, Sutherland CA, Nightingale CH, Nicolau DP.

Pharmacotherapy. 2003 Aug;23(8):988-91.

PMID:
12921245
50.

Pharmacodynamic profile of daptomycin against Enterococcus species and methicillin-resistant Staphylococcus aureus in a murine thigh infection model.

Dandekar PK, Tessier PR, Williams P, Nightingale CH, Nicolau DP.

J Antimicrob Chemother. 2003 Sep;52(3):405-11. Epub 2003 Aug 13.

PMID:
12917254

Supplemental Content

Loading ...
Support Center